Obermatt
See Similar Stocks →

Milestone Pharmaceuticals

NSQ:MIST · CA59935V1076
PharmaceuticalsSmall

360

4
Profit price49
Owner Earnings Yield1
Dividend Yield1
Price/Sales25
EV / Gross Profit6
Price/Book82
Return on Capital21
Cash Return on Capital1
Return on Equity6
Profit margins11
Accruals3
Owner Earnings Margin1
Sales growth93
Profit growth28
Reinvestment16
Price momentum16
Debt load14
Refinancing12
Debt Payback1
Liquidity36
Analyst ratings48
Expectations trend50
Market mood17
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Milestone Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 2/5 components.

Profile

CountryCanada
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2003
Employees105
Websitemilestonepharma.com
ISINCA59935V1076
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CardiovascularBiotechnologyHealth CareTherapeutics

Description

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. The company intends to commercialize and develop CARDAMYST (also known as etripamil) in the United…

Analysis

Story stock

Milestone Pharmaceuticals Inc. trades at an expensive price on a weak set of business metrics, a combination we flag as a story stock.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
6
2026

All-time high

45

Mar 2026

All-time low

6

Jun 2026

Average rank

26

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
25
—
—
—
Price/Earnings
50
—
—
—
Price/Book
82
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
47
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Milestone Pharmaceuticals with its peers
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
LENZ Therapeutics
NSQ:LENZ
11
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Assertio Therapeutics
NAQ:ASRT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →